Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
NetScientific ( (GB:EMVC) ) has provided an update.
EMV Capital’s portfolio company, ProAxsis Ltd, is progressing financially and operationally, leveraging its proprietary technology in chronic respiratory disease diagnostics. ProAxsis has significantly increased its revenue and reduced losses and costs while expanding its market and strengthening partnerships. The company has launched a fundraising initiative to raise up to £800,000 to further commercial and clinical progress, aiming to reach profitability. The funds will support core business activities and a clinical study in COPD in collaboration with Imperial College London, which could enhance ProAxsis’s market position and stakeholder value.
More about NetScientific
EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. It focuses on generating superior returns for investors through capital-efficient investments, fund management, and syndicated investments in early-stage, IP-rich companies. EMV Capital supports its portfolio companies via proactive management and board representation, with a presence in London and Cambridge, and is quoted on the AIM market of the London Stock Exchange.
YTD Price Performance: -0.21%
Average Trading Volume: 42,827
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £13.47M
See more data about EMVC stock on TipRanks’ Stock Analysis page.